<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200511047404N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-04</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Quercus (Oak Gal) on Pelvic Floor Muscle and Sexual Function in Post- Menopausal Women</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Vaginal gel of Quercus (Oak Gal) on Pelvic Floor Muscle’s Strength and Sexual Function in Post- Menopausal Women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48154</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Preparation of vaginal gel of oak Gall by pharmacist
It will be built in the laboratory of Ahvaz School of Pharmacy. In order to reduce the likelihood of bias, allocation concealment selection is performed using unique codes in each of the treatments, so that the researcher and volunteers participating in the study and statistical analysis of the drug or the placebo of vaginal gels are completely unaware. Vaginal gel tubes are filled by the pharmacist.The vaginal gel of the oak Gall and the placebo are numbered and packaged in sequences in the similar envelopes, respectively. The drug envelopes are then given to control and intervention groups. Group allocation is random, and using locks  of 4 and a one-to-one allocation ratio, individuals are divided into two groups of 50 intervention and control. To hide the allocation and prevent bias, the numbers of the intervention and control groups are placed in closed envelopes then are delivered to the eligible participants by the secretary of the menopausal clinic. Each person is given an envelope containing 1 60-gram tube of vaginal gel for 4 weeks to use, and the drug code is included.
The person's checklist is recorded, Blinding description: This study is a triple-blind clinical trial study(researcher, participant, statistical analyst) and coding of vaginal gel tubes is done by a pharmacist.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Loosening of the pelvic floor muscles. Condition 2: Sexual Dysfunction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Vaginal gel with a concentration of 2.5% made in the laboratory of Ahvaz School of Pharmacy is given to postmenopausal women daily for 12 weeks. Intervention 2: Control group: The control group includes 50 samples that receive the placebo vaginal gel made in the laboratory of Ahwaz School of Pharmacy for 12 weeks and daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Demographic information of individuals and data before and after the intervention is reported without mentioning the name.

When:
Access started in 1400.

To whom:
Only researcher in the filed of medical universities

Conditions:
It can only be used in similar research

Where to obtain:
Researcher's personal email

How to obtain:
According to the publication of the article and the registration of the information  of the responsible author, the applicant will contact the responsible author to receive the data by academic email and the information will be sent after the approval of the academic email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sahar Omidianpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan Blv</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135715794</zip>
        <telephone>+98 61 3373 8333</telephone>
        <email>omidianpour.2019@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parvaneh Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan Blv</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135539345</zip>
        <telephone>+98 61 3373 8333</telephone>
        <email>mousavip2009@yahoo.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Not menstruating for the past 12 months
Sexual Function score less than 26.5
Have literacy
Score 28 or less with the prinometer</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Chronic diseases
Smoking and alcohol consumption
Vaginal or cervical infection
Getting uterine bleeding or spotting for an unknown reason
Taking any type of vaginal medication
Breast disease with a specific cause
People with grade 3 and 4 pelvic floor muscle relaxation syndrome based on pop-Q
Experiencing adverse or stressful events in a woman or her husband</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code>F52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword>Sexual dysfunction not due to a substance or known physiological condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Vaginal gel with a concentration of 2.5% made in the laboratory of Ahvaz School of Pharmacy is given to postmenopausal women daily for 12 weeks.</i_keyword>
      <i_keyword>Control group: The control group includes 50 samples that receive the placebo vaginal gel made in the laboratory of Ahwaz School of Pharmacy for 12 weeks and daily.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pelvic floor muscle`s strength. Timepoint: Before the intervention, 4,8and 12 weeks after the start of use of the vaginal gel of the oak Gall. Method of measurement: prinometry.</prim_outcome>
      <prim_outcome>Percentage of people with improved Sexual function. Timepoint: Before the intervention, 4,8and 12 weeks after the start of use of the  vaginal gel of the oak Gall. Method of measurement: Sexual Function Index Questionnaire.</prim_outcome>
      <prim_outcome>Sexual Function Score in the Sexual Function index Questionnaire. Timepoint: Before the intervention, 4,8and 12 weeks after the start of use of the  vaginal gel of the oak Gall. Method of measurement: Questionnaire FSFI.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-10</approval_date>
        <contact_name>Ethics in Biomedical Research</contact_name>
        <contact_address>Golestan Blv, Nursing And Midwifery Department Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
